Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in clinical practice and drug registries give us information to support their use. Adalimumab (ADA) is able to induce a comprehensive disease control in RA by achieving clinical, functional and radiographic control.
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries / V. Codullo, F. Iannone, L. Sinigaglia, E.G. Favalli, P. Sarzi-Puttini, F. Atzeni, G. Ferraccioli, E. Gremese, A. Carletto, A. Giollo, M. Govoni, F. Bergossi, M. Galeazzi, L. Cantarini, F. Salaffi, M. Di Carlo, C. Bazzani, R. Pellerito, M. Sebastiani, R. Ramonda, G. Lapadula, R. Caporali. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 35:4(2017), pp. 660-665.
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries
E.G. Favalli;P. Sarzi-Puttini;
2017
Abstract
Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in clinical practice and drug registries give us information to support their use. Adalimumab (ADA) is able to induce a comprehensive disease control in RA by achieving clinical, functional and radiographic control.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Comparison of efficacy of first- versus second-line.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
334.31 kB
Formato
Adobe PDF
|
334.31 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
